✦ LIBER ✦

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials

✍ Scribed by Massimo Di Maio; Nicola Lama; Alessandro Morabito; Egbert F. Smit; Vassilis Georgoulias; Koji Takeda; Elisabeth Quoix; Dora Hatzidaki; Floris M. Wachters; Vittorio Gebbia; Chun-Ming Tsai; Carlos Camps; Wolfgang Schuette; Paolo Chiodini; Maria Carmela Piccirillo; Francesco Perrone; Ciro Gallo; Cesare Gridelli

Book ID: 116430252
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 433 KB
Volume: 46
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2009.12.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic score for second-line chemoth

Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel

✍ Di Maio, Massimo; Krzakowski, Maciej; Fougeray, Ronan; Kowalski, Dariusz M.; Gri 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 505 KB

Gefitinib Compared with Systemic Chemoth

Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials

✍ F. Wang; L.D. Wang; B. Li; Z.X. Sheng 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 835 KB

A randomised comparison of radical radio

A randomised comparison of radical radiotherapy with or without chemotherapy for patients with non-small cell lung cancer: Results from the Big Lung Trial

✍ David Fairlamb; Robert Milroy; Nicole Gower; Mahesh Parmar; Michael Peake; Robin 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 212 KB

A phase II clinical trial of celecoxib c

A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression

✍ Jun Zhao; Zhi-jie Wang; Jian-chun Duan; Qing-zhi Guo; Hua Bai; Lu Yang; Tong-ton 📂 Article 📅 2009 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 521 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB

P-558 Clinical factors that Influence th

P-558 Clinical factors that Influence the hazard of death In advanced non-small cell lung cancer NSCLC patients treated with platinum-based chemotherapy: Analysis of Individual patient data from prospective trials In monocentric setting

✍ Radosavljevic, D.; Kezic, I.; Jelic, S.; Gavrilovic, D.; Tomasevic, Z. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 289 KB